UCB0022 for Parkinson's Disease
(ATLANTIS Trial)
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial does not specify that you need to stop taking your current medications. In fact, it requires participants to be on a stable dose of standard-of-care treatments, including levodopa therapy.
Will I have to stop taking my current medications?
The trial does not specify that you need to stop taking your current medications. In fact, it requires participants to continue their stable dose of standard Parkinson's treatments, including levodopa.
What data supports the idea that UCB0022 for Parkinson's Disease (also known as: Placebo, Control, Dummy Treatment, UCB0022, Glovadalen) is an effective treatment?
The available research shows that UCB0022, which is essentially a placebo, can lead to improvements in Parkinson's Disease symptoms. In several studies, patients who received a placebo showed significant improvements in their motor function, with some experiencing up to a 50% improvement in their symptoms. This suggests that the belief in receiving treatment can have a real impact on patients' conditions. However, it's important to note that these improvements are not due to the treatment itself but rather the placebo effect, which is the body's response to the belief that it is being treated. Therefore, while UCB0022 can lead to improvements, it is not an effective treatment in the traditional sense, as it does not contain active ingredients that directly address the disease.12345
What data supports the effectiveness of the drug UCB0022 for Parkinson's Disease?
The research highlights that placebo treatments can lead to improvements in Parkinson's disease symptoms, suggesting that patient expectations and psychological factors can significantly influence outcomes. This indicates that any observed benefits of UCB0022 in trials may be partly due to placebo effects, which are genuine biological responses.12345
What safety data exists for UCB0022 in treating Parkinson's Disease?
The provided research does not mention UCB0022, Glovadalen, or any related names directly. The studies focus on other treatments like ropinirole and dopamine agonists, assessing their safety and efficacy in Parkinson's Disease. Therefore, no specific safety data for UCB0022 is available in the provided research.678910
Is the drug UCB0022 a promising treatment for Parkinson's Disease?
What is the purpose of this trial?
This trial is testing UCB0022, a new medication, to see if it can help people with advanced Parkinson's Disease. It is added to their regular treatments to see if it reduces the time they spend with bad symptoms. The goal is to make their usual treatments work better.
Research Team
UCB Cares
Principal Investigator
001 844 599 2273
Eligibility Criteria
This trial is for adults aged 35-80 with advanced Parkinson's Disease who experience significant daily motor fluctuations and are responsive to levodopa therapy. They should be in stages I-III of disease severity, diagnosed with PD for at least 5 years, able to track their symptoms, and agree not to share study info on social media.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive UCB0022 or placebo as an adjunctive treatment to stable dose of standard-of-care for Parkinson's Disease
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Placebo
- UCB0022
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven